OMNIPAQUE 300 Drug Patent Profile
✉ Email this page to a colleague
When do Omnipaque 300 patents expire, and when can generic versions of Omnipaque 300 launch?
Omnipaque 300 is a drug marketed by Ge Healthcare and is included in two NDAs.
The generic ingredient in OMNIPAQUE 300 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMNIPAQUE 300?
- What are the global sales for OMNIPAQUE 300?
- What is Average Wholesale Price for OMNIPAQUE 300?
Summary for OMNIPAQUE 300
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 98 |
Clinical Trials: | 25 |
Patent Applications: | 3,518 |
DailyMed Link: | OMNIPAQUE 300 at DailyMed |
Recent Clinical Trials for OMNIPAQUE 300
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Fédération des médecins résidents du Québec | Phase 4 |
Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal | Phase 4 |
Claire Bourgeois | Phase 4 |
Pharmacology for OMNIPAQUE 300
Drug Class | Radiographic Contrast Agent |
Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for OMNIPAQUE 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | OMNIPAQUE 300 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-003 | Dec 26, 1985 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Ge Healthcare | OMNIPAQUE 300 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 020608-002 | Oct 24, 1995 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMNIPAQUE 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ge Healthcare | OMNIPAQUE 300 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-003 | Dec 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
Ge Healthcare | OMNIPAQUE 300 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-003 | Dec 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
Ge Healthcare | OMNIPAQUE 300 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-003 | Dec 26, 1985 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OMNIPAQUE 300
See the table below for patents covering OMNIPAQUE 300 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 1132901 | AGENT DE CONTRASTAGE AUX RAYONS X A BASE D'ANILINE ET TAMPON DONT LE PH S'ABAISSE AVEC LA TEMPERATURE (ANILINE X-RAY AGENT AND BUFFER WHOSE PH DECREASES WITH TEMPERATURE) | ⤷ Sign Up |
South Africa | 7903313 | ⤷ Sign Up | |
Philippines | 10017 | NOVEL IODINATED X-RAY CONTRAST AGENTS | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |